Drug Search Results
More Filters [+]

Perampanel

Alternative Names: perampanel, fycompa, e2007
Latest Update: 2024-06-10
Latest Update Note: Clinical Trial Update

Product Description

 Perampanel is a potentially broad-spectrum antiepileptic drug with a novel mechanism of action that may be a useful addition for patients with epilepsy with various seizure types. The availability of novel antiepileptic drugs for epilepsy treatment enables more individualized treatment for these patients. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29953584/)

Mechanisms of Action: AMPA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Perampanel

Countries in Clinic: Belgium, Czech Republic, Denmark, France, Germany, Japan, Latvia, Spain, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Epilepsy, Generalized|Epilepsy, Tonic-Clonic|Lennox Gastaut Syndrome|Seizures

Phase 2: Epilepsy|Glioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020-002109-24

P3

Active, not recruiting

Seizures

2028-09-07

E2007-G000-236

P2

Recruiting

Epilepsy

2024-10-06

32%

2P50CA165962-06A1

P2

Completed

Seizures|Glioma

2023-05-16

E2007-G000-238

P2

Completed

Epilepsy

2022-08-23

Recent News Events